5 Things to Know From the JP Morgan Healthcare Conference
Five highlights from our coverage of the 37th Annual JP Morgan Healthcare Conference.
Each year, healthcare, pharmaceutical, and biotechnology executives attend the JP Morgan Healthcare Conference, some to tout recent developments, others just to bounce from session to session. Here are 5 focus areas, with highlights from the 37th annual conference that met in San Francisco from January 7 to 10.
Focus on Specificity
The FDA’s Scott Gottlieb, MD, spoke by video (because of the government shutdown) about new plans by the agency to modernize its drug development review process, including the use and validation of biomarkers, bioinformatics, and patient-reported outcomes to better predict who would respond to a potential therapeutic target. The commissioner announced a new the Office of Drug Evaluation Science, which will begin with a structured review of safety data.
At a session on precision medicine, the chief executive officers of Exact Sciences Corporation and Adaptive Biotechnologies Corporation discussed how past investments are paying off to tailor treatments and even predict illness years before it occurs.
Focus on Acquisitions
Planned, separate sessions by Bristol-Meyers Squibb and Celgene were combined, as the conference kicked off with the announcement of their
Meanwhile, Eli Lilly’s planned presentation focused heavily on its announcement that it would buy biotech firm Loxo Oncology for $8 billion. Loxo focuses on inhibiting cancer tumors exhibiting genetic mutations regardless of where they are in the body.
Focus on Digital Health
One company touted a recent acquisition to show how it plans to use digital health to tackle one of the world’s top drivers of chronic disease burdens. The chief executive officer of ResMed, Michael Farrell laid out the company’s strategy to 2025. ResMed
Focus on Biosimilars
Focus on Consumers and Value
Biotech company
Meanwhile, the chief executive officer and president of CVS Health
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Eating Behaviors May Predict GLP-1 Therapy Success in Type 2 Diabetes
September 18th 2025
- Modest Reductions in PrEP Coverage Result in Avoidable HIV Infections
September 17th 2025